Trishna Goswami
Chief Tech/Sci/R&D Officer chez IN8BIO, INC.
Fortune : 7 940 $ au 31/03/2024
Profil
Trishna Goswami is currently the Chief Medical Officer at IN8bio, Inc. Prior to this, she was the Vice President of Clinical Development at Immunomedics, Inc. from 2018 to 2021.
She also worked as the Senior Director of Medical at Stemline Therapeutics, Inc. from 2017 to 2018.
Dr. Goswami's education includes an MBA from Robert H.
Smith School of Business and a doctorate from Drexel University College of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IN8BIO, INC.
0,02% | 07/02/2024 | 6 729 ( 0,02% ) | 7 940 $ | 31/03/2024 |
Postes actifs de Trishna Goswami
| Sociétés | Poste | Début |
|---|---|---|
| IN8BIO, INC. | Chief Tech/Sci/R&D Officer | 16/11/2021 |
Anciens postes connus de Trishna Goswami
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOMEDICS, INC. | Corporate Officer/Principal | 01/12/2021 |
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Formation de Trishna Goswami
| Robert H. Smith School of Business | Masters Business Admin |
| Drexel University College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
| IN8bio, Inc. |
